JP6433913B2 - アントラサイクリン製剤 - Google Patents

アントラサイクリン製剤 Download PDF

Info

Publication number
JP6433913B2
JP6433913B2 JP2015547985A JP2015547985A JP6433913B2 JP 6433913 B2 JP6433913 B2 JP 6433913B2 JP 2015547985 A JP2015547985 A JP 2015547985A JP 2015547985 A JP2015547985 A JP 2015547985A JP 6433913 B2 JP6433913 B2 JP 6433913B2
Authority
JP
Japan
Prior art keywords
cancer
injectable composition
anthracycline compound
emch
doxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015547985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503026A5 (https=
JP2016503026A (ja
Inventor
スコット ガイヤー，
スコット ガイヤー，
ダニエル レビット，
ダニエル レビット，
キャリー ノッドガード，
キャリー ノッドガード，
エドワード エイチ． トラッペラー，
エドワード エイチ． トラッペラー，
Original Assignee
サイトレックス コーポレイション
サイトレックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトレックス コーポレイション, サイトレックス コーポレイション filed Critical サイトレックス コーポレイション
Publication of JP2016503026A publication Critical patent/JP2016503026A/ja
Publication of JP2016503026A5 publication Critical patent/JP2016503026A5/ja
Application granted granted Critical
Publication of JP6433913B2 publication Critical patent/JP6433913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015547985A 2012-12-13 2013-12-13 アントラサイクリン製剤 Active JP6433913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737003P 2012-12-13 2012-12-13
US61/737,003 2012-12-13
PCT/US2013/075002 WO2014093815A1 (en) 2012-12-13 2013-12-13 Anthracycline formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145172A Division JP6833768B2 (ja) 2012-12-13 2018-08-01 アントラサイクリン製剤

Publications (3)

Publication Number Publication Date
JP2016503026A JP2016503026A (ja) 2016-02-01
JP2016503026A5 JP2016503026A5 (https=) 2017-01-19
JP6433913B2 true JP6433913B2 (ja) 2018-12-05

Family

ID=50934989

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015547985A Active JP6433913B2 (ja) 2012-12-13 2013-12-13 アントラサイクリン製剤
JP2018145172A Active JP6833768B2 (ja) 2012-12-13 2018-08-01 アントラサイクリン製剤
JP2019147584A Withdrawn JP2019206583A (ja) 2012-12-13 2019-08-09 アントラサイクリン製剤
JP2021085891A Active JP7213303B2 (ja) 2012-12-13 2021-05-21 アントラサイクリン製剤
JP2021085892A Pending JP2021120415A (ja) 2012-12-13 2021-05-21 アントラサイクリン製剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018145172A Active JP6833768B2 (ja) 2012-12-13 2018-08-01 アントラサイクリン製剤
JP2019147584A Withdrawn JP2019206583A (ja) 2012-12-13 2019-08-09 アントラサイクリン製剤
JP2021085891A Active JP7213303B2 (ja) 2012-12-13 2021-05-21 アントラサイクリン製剤
JP2021085892A Pending JP2021120415A (ja) 2012-12-13 2021-05-21 アントラサイクリン製剤

Country Status (7)

Country Link
US (2) US20150342975A1 (https=)
EP (2) EP3915369A1 (https=)
JP (5) JP6433913B2 (https=)
AU (1) AU2013359048A1 (https=)
CA (1) CA2894548C (https=)
DK (1) DK2931042T3 (https=)
WO (1) WO2014093815A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120414A (ja) * 2012-12-13 2021-08-19 サイトレックス コーポレイション アントラサイクリン製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113842392A (zh) * 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂
US11393557B2 (en) 2015-08-25 2022-07-19 Nantomics, Llc Systems and methods for high-accuracy variant calling
US11071812B2 (en) * 2016-05-31 2021-07-27 Penumbra, Inc. Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood
EP3668538A4 (en) 2017-08-15 2021-06-16 NantCell, Inc. HANK-CETUXIMAB COMBINATIONS AND PROCEDURES
WO2020081174A1 (en) 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JP2915252B2 (ja) 1993-06-30 1999-07-05 明治製菓株式会社 溶解性が改善された製剤の製造法
EP0954283B1 (en) * 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
JP5634862B2 (ja) * 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
EP2216049A1 (en) * 2009-02-06 2010-08-11 Freie Universität Berlin Drug conjugates with polyglycerols
MX2011004019A (es) * 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
EP3915369A1 (en) * 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120414A (ja) * 2012-12-13 2021-08-19 サイトレックス コーポレイション アントラサイクリン製剤
JP7213303B2 (ja) 2012-12-13 2023-01-26 サイトレックス コーポレイション アントラサイクリン製剤

Also Published As

Publication number Publication date
EP3915369A1 (en) 2021-12-01
CA2894548C (en) 2021-01-12
JP7213303B2 (ja) 2023-01-26
EP2931042A4 (en) 2016-06-01
US20150342975A1 (en) 2015-12-03
JP2018165280A (ja) 2018-10-25
EP2931042B1 (en) 2021-04-28
WO2014093815A1 (en) 2014-06-19
US10328093B2 (en) 2019-06-25
US20170340655A1 (en) 2017-11-30
CA2894548A1 (en) 2014-06-19
JP2021120414A (ja) 2021-08-19
JP2019206583A (ja) 2019-12-05
JP2021120415A (ja) 2021-08-19
AU2013359048A1 (en) 2015-07-02
JP2016503026A (ja) 2016-02-01
JP6833768B2 (ja) 2021-02-24
DK2931042T3 (da) 2021-06-07
EP2931042A1 (en) 2015-10-21
HK1209973A1 (en) 2016-04-15

Similar Documents

Publication Publication Date Title
JP7213303B2 (ja) アントラサイクリン製剤
US10881678B2 (en) Cytotoxic agents for the treatment of cancer
JP2003063965A (ja) 注射用シロスタゾール水性製剤
HU217806B (hu) Eljárás polimerhez kötött antraciklin-glikozidokat tartalmazó gyógyszerkészítmények előállítására
TW200306314A (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
BR112013005763B1 (pt) Injeção de 5a-androstano-3ss, 5, 6ss-triol e método para prrparação da injeção
JP2016534062A (ja) 新規な安定製剤
KR102270619B1 (ko) 고분자화 약물 함유 약제학적 조성물
HK1209973B (en) Anthracycline formulations
KR20240040118A (ko) 약물 제제, 이의 제조 방법 및 용도
WO2021011488A1 (en) Compositions comprising aldoxorubicin hydrochloride and ifosfamide and their use for the treatment of soft tissue sarcoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181107

R150 Certificate of patent or registration of utility model

Ref document number: 6433913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250